TABLE 3.
Management and follow-up.
| All patients (n = 154) | MIT (n = 64) | Fumagillin (n = 54) | Nitazoxanide (n = 36) | p | |
|---|---|---|---|---|---|
| Immunosuppressive treatment at day 0 | |||||
| Tacrolimus | 134 (87.0) | 58 (90.6) | 50 (92.6) | 26 (72.2) | 0.02 |
| Trough levels (ng/L) (n = 121) | 10.0 [6.6; 14.7] | 9.9 [7.1; 13.9] | 9.8 [5.5; 14.7] | 11.2 [6.5; 14.8] | 0.85 |
| Trough levels >10 ng/L | 60/121 (49.6) | 25/52 (48.1) | 24/48 (50.0) | 11/21 (52.4) | 0.94 |
| Mycophenolate mofetil | 128 (83.1) | 51 (79.7) | 49 (90.7) | 28 (77.8) | 0.17 |
| Dose (g/day) (n = 124) | 1.0 [1.0; 1.5] | 1.0 [1.0; 1.0] | 1.0 [1.0; 1.5] | 1.0 [0.8; 1.5] | 0.63 |
| Steroids | 105 (68.2) | 45 (70.3) | 38 (70.4) | 22 (61.1) | 0.58 |
| Dose (mg/day) (n = 103) | 5.0 [5.0; 10.0] | 5.0 [5.0; 5.0] | 7.5 [5.0; 10.0] | 5.0 [5.0; 10.0] | 0.003 |
| Everolimus | 15 (9.7) | 9 (14.1) | 2 (3.7) | 4 (11.1) | 0.14 |
| Dose (mg/day) (n = 15) | 2.0 [1.5; 3.0] | 2.0 [2.0; 4.0] | 2.5 [2.0; 3.0] | 1.5 [1.3; 1.8] | 0.15 |
| Cyclosporine | 14 (9.1) | 3 (4.7) | 2 (3.7) | 9 (25.0) | 0.002 |
| Dose (mg/day) (n = 13) | 120 [100; 200] | 160 [60; 400] | 85 [50; 120] | 120 [110; 200] | 0.41 |
| Azathioprine | 5 (3.3) | 2 (3.1) | 2 (3.7) | 1 (2.8) | 1.00 |
| Dose (mg/day) (n = 4) | 88 [63; 100] | 63 [50; 75] | 100 | 100 | 0.26 |
| Belatacept | 4 (2.6) | 1 (1.6) | 3 (5.6) | 0 | 0.36 |
| Dose (mg/day) (n = 4) | 340 [265; 395] | 380 | 300 [230; 410] | — | 0.65 |
| Follow-up and outcome | |||||
| Clinical remission | 134 (87.0) | 57 (89.1) | 49 (90.7) | 28 (77.8) | 0.23 |
| Time from first symptoms to clinical remission (days) (n = 76) | 10 [5; 21] | 8 [5; 15] | 14 [7; 24] | 9 [5; 25] | 0.28 |
| Serum creatinine at month 3 (µmol/L) (n = 126) | 144 [115; 203] | 137 [110; 195] | 159 [116; 203] | 139 [117; 209] | 0.69 |
| Microsporidia stool monitoring | 72 (46.8) | 22 (34.4) | 36 (66.7) | 14 (38.9) | 0.08 |
| Stool negativization rate | 50/72 (69.4) | 13/22 (59.1) | 33/36 (91.7) | 4/14 (28.6) | 0.002 |
| Relapse | 10/145 (6.9) | 4/57 (7.0) | 1/53 (1.9) | 5/35 (14.3) | 0.13 |
| Organ failure at month 12 | 1/101 (1.0) | 0/50 (0.0) | 0/23 (0.0) | 1/28 (3.6) | 0.51 |
| Death at month 12 | 1/124 (0.8) | 0/50 (0.0) | 1/47 (2.1) | 0/27 (0.0) | 0.60 |
Data are presented as number of patients (percentages), or median [25th; 75th percentiles]. Comparisons between groups for immunosuppressive treatment at day 0 were made with Chi-squared test or Fisher’s exact test for categorical data, and with Kruskal-Wallis test for quantitative data. Comparisons between groups for outcomes were made with linear or generalized linear mixed models, with the center as random effect. In the first column, “n” is the number of available data when there is missing data. MIT: modification of immunosuppressive treatment.